Insider Trading March 23, 2026

American Coastal Insurance Director Adds $2,210 to Stake with 200-Share Purchase

Davis Kern Michael increases direct holdings as Oppenheimer launches coverage with a Perform rating

By Hana Yamamoto ACIC
American Coastal Insurance Director Adds $2,210 to Stake with 200-Share Purchase
ACIC

Director Davis Kern Michael bought 200 shares of American Coastal Insurance (ACIC) common stock on March 20, 2026, at $11.05 per share, a transaction valued at $2,210. Following the purchase, Michael directly holds 299,564 shares. The stock trades at a P/E of 5.32 and is flagged as undervalued by InvestingPro Fair Value metrics; the company also yields 6.78% in dividends. Separately, Oppenheimer began coverage of the company with a Perform rating, citing strength in Florida commercial residential insurance and the condominium segment.

Key Points

  • Director Davis Kern Michael purchased 200 shares of ACIC on March 20, 2026, at $11.05 per share, totaling $2,210.
  • After the transaction, Davis directly holds 299,564 shares; First Child and Second Child each hold 4,626 shares. The company trades at a P/E of 5.32 and has a 6.78% dividend yield.
  • Oppenheimer initiated coverage with a Perform rating, highlighting American Coastal’s strength in Florida commercial residential insurance and particularly the condominium segment, noting consistently superior margins there.

Director Davis Kern Michael of American Coastal Insurance (NASDAQ: ACIC) executed an insider purchase on March 20, 2026, acquiring 200 shares of common stock at a price of $11.05 per share. The total value of the transaction was $2,210.

After this buy, Davis Kern Michael directly holds 299,564 shares of American Coastal Insurance. Additional family holdings reported include 4,626 shares held by First Child and 4,626 shares held by Second Child.

Market data noted alongside the filing indicates ACIC trades at a price-to-earnings ratio of 5.32. According to InvestingPro Fair Value metrics cited in the filing, the stock is presently viewed as undervalued. The company also provides a dividend yield of 6.78%, a figure highlighted as a potential attraction for investors focused on income. InvestingPro subscribers are noted to have access to six additional exclusive tips about ACIC.


In separate analyst developments, Oppenheimer has initiated coverage of American Coastal Insurance Corp. with a Perform rating. The coverage report emphasizes American Coastal’s substantial presence in the Florida commercial residential insurance market, underscoring particular success in the condominium segment and consistently stronger margins in that area. Oppenheimer’s Perform rating implies a neutral stance, indicating the stock is expected to perform roughly in line with the broader market.

Taken together, the insider purchase and the new analyst coverage provide concurrent data points for investors assessing American Coastal’s current valuation, dividend income profile, and segment-level profitability. The filing and the coverage note contain the specific ownership, valuation and rating details summarized here.


Is ACIC a bargain? The filing references InvestingPro Fair Value metrics and dividend yield as inputs investors might consider when evaluating the stock’s appeal. The report also notes that InvestingPro subscribers can access six additional tips regarding ACIC.

Risks

  • Neutral analyst rating - Oppenheimer’s Perform rating indicates a market-aligned outlook rather than a positive endorsement, which may limit upside expectations for equity investors. (Impacted sectors: Insurance, Financials)
  • Valuation and income trade-offs - while InvestingPro metrics label the stock as undervalued and the dividend yield is 6.78%, the information provided does not guarantee future performance or dividend stability. (Impacted sectors: Income-focused equity investors, Insurance)

More from Insider Trading

Spyre Therapeutics CFO Disposes $370K in Stock, Exercises Options Same Day as Trial Timelines Accelerate Apr 3, 2026 Fold Holdings CEO completes modest stock sale to cover RSU tax obligations Apr 3, 2026 Spyre Therapeutics CEO Executes $739,912 Stock Sale as Trials Accelerate Apr 3, 2026 Spyre Therapeutics CMO Sells Shares, Exercises Options as Trials Accelerate Apr 3, 2026 Fold CFO Sells Small Stake to Meet Tax Withholding as Company Faces Revenue Shortfall Apr 3, 2026